Fruquintinib Maintenance Therapy for Advanced CRC After Adjuvant Chemotherapy: A Study on 2-Year Recurrence and Metastasis Rate
Explore the clinical efficacy and safety of fruquintinib as a maintenance treatment for advanced colorectal cancer (CRC) achieving no evidence of disease (NED) after completing adjuvant chemotherapy, with a focus on the 2-year recurrence and metastasis rate as the primary endpoint.
原文地址: https://www.cveoy.top/t/topic/fww6 著作权归作者所有。请勿转载和采集!